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Abstract. Background: Neutropenic patients are susceptible to any anorectal disease, and 
symptomatic anorectal disease afflicts 2-32% of oncology patients. Perianal infections are the 
most feared complication, considering the lack of natural defense against infectious 
microorganisms. When septic complications develop, the anorectal disease is potentially fatal, 
especially in neutropenic patients in whom mortality rates range between 11-57%. Although 
anorectal diseases are a frequent complication with potentially fatal outcomes among patients 
with hematologic diseases, sufficient data are not available in the literature. In this study, we 
aimed to investigate the anorectal complications developing during the neutropenic period in 
patients with hematologic diseases.  
Methods: A total of 79 patients whose neutropenic period (absolute neutrophil count <500/mcL) 
continued for 7 days, or longer were included in the study.  
Results: A total of 34 patients out of 79 (43%) were detected to develop anorectal complications, 
of them 6 (7.6%) developed an anorectal infection. The patients were characterized according to 
the hematological disease and its status (active or not), the type of treatment and the presence of 
a history of an anorectal pathology before the onset of the hematologic disease. Nineteen (24.1%) 
patients had the history of anorectal disturbances before diagnosis of the hematologic disease, 
and recurrence of an anorectal pathology was found in 14 out of 19 patients(73.7%). In addition, 
the overall mortality rate was higher among the patients who developed anorectal complications 
compared to another group (41.2% vs. 22.2%, p=0.059). 
Conclusion: Anorectal pathology is a common complication with high recurrence rate in 
neutropenic patients. Perianal infections are important as they can cause life-threatening 
outcomes although they are relatively rare among all anorectal complications. Therefore 
perianal signs and symptoms should be meticulously evaluated concerning early diagnosis and 
treatment. 
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Introduction. Febrile neutropenia is an important 
cause of mortality occurring commonly after 
myelosuppressive treatment in cancer patients.
1,2
 
Neutropenic patients are susceptible to any anorectal 
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complications,
3
 and symptomatic anorectal pathology 
afflicts 2-32% of oncology patients.
4
 Perianal 
infections (represented by an abscess or infected 
fistula) are the most feared complication, considering 
the lack of natural defense against infectious 
microorganisms.
3
 The incidence of perianal infection is 
approximately 8-9% of patients with acute leukemia.
5
 
When septic complications develop, the anorectal 
disease is potentially fatal, especially in neutropenic 
patients, in whom mortality rates range from 11-57%.
4
 
Although anorectal diseases are a frequent 
complication with potentially fatal outcomes among 
patients with hematologic diseases, sufficient data are 
not available in the literature. In this study, we aimed 
to investigate the anorectal complications developing 
during the neutropenic period in patients with 
hematologic diseases. 
Methods and Patients. This study was conducted as a 
retrospective, cross-sectional, single-center 
investigation. A total of 79 patients, admitted to our 
clinic between 01 November 2014 and 01 November 
2015, with a diagnosis of acute myeloid leukemia 
(AML), acute lymphoblastic leukemia (ALL), 
myelodysplastic syndrome (MDS), Hodgkin lymphoma 
(HL), non-Hodgkin lymphoma (NHL), multiple 
myeloma (MM) and aplastic anemia (AA), whose 
neutropenic period (absolute neutrophil count 
<500/mcL) continued for 7 days or longer, were 
included in the study. Anorectal problems were defined 
according to anamnesis, physical examination findings, 
gastroenterology and general surgery consultations, 
and imaging methods (pelvic computer tomography or 
magnetic resonance imaging) when required. 
 
 
Table 1. Clinical characteristics of the patients. 
 n % 
Gender 
 Male 
 Female 
 
49 
30 
 
62.0 
38.0 
Diagnosis 
 Acute myeloid leukemia 
 Acute lymphoblastic leukemia 
 Lymphoma 
 Multiple myeloma 
 Myelodysplastic syndrome 
 Aplastic Anemia 
 
34 
14 
13 
10 
5 
3 
 
43.0 
17.7 
16.5 
12.7 
6.3 
3.8 
Number of comorbidity 
 No 
 1 
 2 
 
57 
19 
3 
 
72.2 
24.1 
3.8 
Disease status 
 Active Disease 
 No Active Disease 
 
41 
38 
 
51.9 
48.1 
ECOG performance status 
 0 
 1 
 2 
 3 
 
22 
44 
8 
5 
 
27.8 
55.7 
10.1 
6.3 
Type of treatment  
 Chemotherapy 
 Hematopoietic stem cell transplantation 
 Other 
 
43 
35 
1 
 
54.4 
44.3 
1.3 
Use of Corticosteroid 28 35.4 
Neutropenic fever 
 No 
 Yes 
 
18 
61 
 
22.8 
77.2 
History of anorectal disease before diagnosis of the hematologic disease 
 No  
 Internal / external hemorrhoidal disease 
 Fissure with or without hemorrhoid 
 Fistula 
 Abscess 
 
60 
13 
5 
1 
0 
 
75.9 
16.5 
6.3 
1.3 
0 
Anorectal complication developing in the course of neutropenic period 
 No 
 Symptomatic internal / external hemorrhoid 
 Fissure with or without hemorrhoid 
 Fistula 
 Abscess 
 
45 
8 
20 
2 
4 
 
57.0 
10.1 
25.3 
2.5 
5.1 
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Patients who had a newly diagnosed disease, or 
refractory, relapsed and progressive were defined as 
the ones who had “an active disease”. Comorbidities 
included diabetes mellitus, hypertension, a pulmonary, 
cardiac, hepatic and renal disease, or a history of a 
previous malignancy other than the current one,  
 
Statistical Analysis: Patient characteristics were 
examined using descriptive statistics. Continuous 
variables were given as mean ± standard deviation 
(SD), and categorical variables were defined as a 
percentage. Chi-square test and t-test were used to 
compare proportions and means for categorical and 
continuous variables, respectively. Statistical 
Significance was defined as p<0.05. All test 
significances were two-tailed. SPSS statistical software 
(SPSS 17.0 for Windows, Inc., Chicago, IL, USA) was 
used for all statistical calculations. 
 
Results. The study included 30 (38%) female and 49 
(62%) male patients with mean age of 42.9±14.4 years 
(44.8±15.6 for women and 41.8±13.7 for men). 
Clinical characteristics of the patients are given in 
Table 1. 
The mean duration of neutropenia period was found 
as 14.6 days (range 7-60). A total of 34 patients out of 
79 (43%) were detected to develop anorectal 
complications, of them 6 (7.6%) developed a perianal 
infection (abscess and fistula). Anorectal complications 
were observed on average by day 12 (0-28) of 
neutropenia, and the period of neutropenia lasted an 
average of 8 days (range 1-60). When the patients were 
compared regarding anorectal complications, the 
patients who developed anorectal complication were 
seen to be older (43.8±14.7 vs. 42.3±14.4 years, 
p=0.661) and stayed neutropenic for a longer period 
(16.7±7.5 vs. 13.7±8.2 days, p=0.102) however the 
difference was not statistically significant for both 
parameters. Comparison of the groups about anorectal 
complications development is given in Table 2. 
Of 6 patients who developed a perianal infection, 
septic shock develop in 3, Fournier’s gangrene 
developed in one, and the overall mortality rate was 
50%. Culture positivity was detected in 2 (33.3%) out 
of 6 patients, and growing microorganisms were 
Pseudomonas aeruginosa and Escherichia coli.  
An anorectal complication was seen to develop in a 
total of 34 (43%) patients during the neutropenic
 
Table 2. Comparison of the groups with regard to anorectal complication development. 
  Anorectal complication  P value 
Yes  
 (n=34) 
No  
(n=45) 
Gender 
 Male 
 Female 
 
22 (64.7%) 
12 (35.3%) 
 
27 (60.0%) 
18 (40.0%) 
0.670 
Diagnosis 
 Acute leukemia and myelodysplastic syndrome 
 Lymphoma and multiple myeloma 
 Aplastic anemia 
 
29 (85.3%) 
5 (14.7%) 
0 
 
24 (53.3%) 
18 (40.0%) 
3 (6.7%) 
0.009 
Number of comorbidity 
 No 
 1 
 2 
 
26 (76.5%) 
7 (20.6%) 
1 (2.9%) 
 
31 (68.9%) 
12 (26.7%) 
2 (4.4%) 
0.753 
Active disease 
 Yes 
 No 
 
23 (67.6%) 
11 (32.4%) 
 
18 (40.0%) 
27 (60.0%) 
0.015 
ECOG performance status 
 0 
 1 
 2 
 3 
 
8 (23.5%) 
19 (55.9%) 
4 (11.8%) 
3 (8.8%) 
 
14 (31.1%) 
25 (55.6%) 
4 (8.9%) 
2 (4.4) 
0.766 
Type of treatment 
 Chemotherapy 
 Hematopoietic stem cell transplantation 
 Other 
 
30 (88.2%) 
3 (8.8%) 
1 (2.9%) 
 
13 (28.9%) 
32 (71.1%) 
0 
0.0001 
Febrile neutropenia 
 No 
 Yes 
 
6 (17.6%) 
28 (82.4%) 
 
12 (26.7%) 
33 (73.3%) 
0.344 
Use of corticosteroid 14 (41.2%) 14 (31.1%) 0.354 
History of anorectal disease before diagnosis of the hematologic disease 
 No 
 Yes 
 
20 (58.8%) 
14 (41.2%) 
 
40 (88.9%) 
5 (11.1%) 
0.005 
Death 
 No 
 Yes 
 
20 (58.8%) 
14 (41.2%) 
 
35 (77.8%) 
10 (22.2%) 
0.059 
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period. Nineteen patients ((24.1%) had the history of 
anorectal diseases before the diagnosis of the 
hematologic disease, and a recurrence of anorectal 
disease was found in 14 out of 19 patients ( 73.7%). Of 
60 patients without previous anorectal diseases 20 
(33,3 %) suffered from an anorectal complication, and 
a statistically significant difference was detected 
between the two groups (p=0.003).). The anorectal 
complication was detected in 29 out of 53 patients (54. 
7%) who had acute leukemia and MDS, in 5 out of 23 
patients (21.7%) who had lymphoma and MM, and no 
anorectal complications developed in AA patients. 
Febrile neutropenia ratio was higher among the patients 
who developed anorectal complications as expected 
although the difference was not significant (82.4% vs. 
73.3%, p=0.344). 
When the groups were compared, the disease type 
(acute leukemia or MDS vs. lymphoma), the presence 
of active disease, the kind of treatment and presence of 
the history of an anorectal pathology before the 
diagnosis of the hematologic disease were influent in 
determining anorectal disease development. On the 
other hand, corticosteroid use was detected not to be 
effective on anorectal complication development. A 
statistically significant difference was not detected 
between the groups which developed and did not 
develop anorectal complications in steroid use (41.2% 
vs. 31.1%, respectively; p=0.354). In addition, the 
overall mortality rate was higher among the patients 
who developed anorectal complications compared to 
another group (41.2% vs. 22.2%, p=0.059). In our 
study, 14 out of 23 patients (60.9%) who developed 
anorectal complications and had an active disease died, 
however, no deaths occurred in 11 patients who 
developed anorectal complications but who did not 
have an active disease. 
 
Discussion. Manifestations of perianal infections may 
differ from those with a competent immune system
3
 
and are often accompanied by severe pain, swelling, 
constipation, and may cause systemic infection.
6
 
However, the clinical presentation of an anorectal 
infection is often masked by the absence of 
inflammatory cells so recognition of the signs and 
symptoms can be difficult in neutropenic patients.
7
 
Perianal infections are a life-threatening complication 
including Fournier’s gangrene that requires rapid 
diagnosis and intervention as recurrence and mortality 
rates may be expressive.
3,8
 In a series of 92 patients 
with acute or chronic leukemia, most common 
manifestations were a perirectal abscess (27%) 
followed by anal fissures (23%), external hemorrhoids 
(19%) and perianal ulcerations (13%).
3
 Another 
retrospective study found a perianal infection 
prevalence of 6.7% and recurrence was diagnosed in 
31% of the cases.
3
 Grewal et al.
4
 reported that 5.8% 
patients hospitalized with leukemia had the 
concomitant symptomatic anorectal disease. Büyükaşık 
et al.
5 
found the incidence of perianal infections in 
acute leukemia as 7.3 percent. We detected that 43% of 
the patients developed anorectal complications, and 
7.6% developed a perianal infection (abscess and 
fistula), consistently with literature. Recurrence of 
anorectal disease was found as 73.7% (14 out of 19 
patients) in our study suggesting that anorectal disease 
development is a common and recurrent complication 
during the neutropenic period. Anorectal complication 
development rate was higher among the patients who 
had an active disease compared to the patients whose 
disease was under control (67.6% vs. 40.0, p=0.015). 
This finding suggests that anorectal complications can 
cause severe morbidity in the presence of an active 
disease. While overall mortality rate was found in 
41.2% of all patients with anorectal complication, this 
proportion increases to 60.9% in the presence of active 
disease together. On the other hand, no deaths occurred 
in 11 patients who had an anorectal complication but 
not an active disease. Similarly to our results, Musa et 
al.
9
 found that the overall mortality was 53% among 17 
adults with hematologic malignancy in whom anorectal 
complications developed, the death rate was 69% for 
those in whom the disease was not in remission 
compared with zero for patients who were in remission. 
However, these data are insufficient for to say that 
anorectal complications increase mortality in patients 
with active disease. 
In literature, no consensus is available for the 
treatment of anorectal complications in neutropenic 
patients together with the lack of studies investigating 
these complications.
5
 Some authors defended operative 
treatment, whereas others reported high mortality rate 
with operative treatment compared with medical 
procedures.
5
 Interestingly, internists reported success 
with surgery or failure with medical treatment; 
however, most of the surgeons were unsatisfied with 
the surgical approach and concluded that surgical 
treatment should be reserved for patients who 
recovered from neutropenia and active disease.
5
 
Grewal et al.
4
 did not observe excessive morbidity or 
mortality in the operated neutropenic patients with 
anorectal disease as compared with the non-operated 
patients. Nowadays, the number of patients requiring 
surgical intervention decreased substantially, which it 
was ascribed to the use of broad-spectrum antibiotics 
coverage of gram-negative and anaerobic bacteria.
7
 We 
had a similar clinical approach; namely, we prefer 
administration of a broad spectrum antibiotic effective 
on gram negative and anaerobic bacteria (usually a 
carbapenem antibiotic) when perianal infection 
develops during the severe neutropenic period. The 
surgical approach is considered in the case of failure of 
medical treatment or persistence of the perianal 
infection even after the restore from neutropenia. 
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Conclusion. An anorectal pathology is a common 
complication with high recurrence rate in neutropenic 
patients. It is a serious cause of morbidity which 
impairs quality of life particularly in patients with 
acute leukemia and MDS, who receive intensive 
chemotherapy and who have an active disease. Perianal 
infections are important as they can cause life-
threatening outcomes although they are relatively rare 
among all anorectal complications. Therefore perianal 
signs and symptoms should be meticulously evaluated 
to do an early diagnosis and treatment.  
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